What are the treatment recommendations for newly diagnosed acute myeloid leukemia (AML) in patients 75 years or older?

Updated: Dec 05, 2018
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

Answer

Glasdegib plus low-dose cytarabine [33]  

  • Glasdegib 100 mg PO once daily on days 1-28 plus cytarabine 20 mg SC BID on days 1-10 of each 28-day cycle for minimum of six cycles

Venetoclax plus low-dose cytarabine (28-day cycle) [34]

  • Day 1: Venetoclax 100 mg PO once
  • Day 2: Venetoclax 200 mg PO once
  • Day 3: Venetoclax 300 mg PO once
  • Day 4 and beyond: Venetoclax 600 mg PO once daily
  • Days 1-10: Cytarabine 20 mg/m 2 SC once daily beginning on cycle 1 day 1
  • Continue until disease progression or unacceptable toxicity

Venetoclax plus azacitidine (28-day cycle) [35]

  • Day 1: Venetoclax 100 mg PO once
  • Day 2: Venetoclax 200 mg PO once
  • Day 3: Venetoclax 300 mg PO once
  • Day 4 and beyond: Venetoclax 400 mg PO once daily; continue until disease progression or unacceptable toxicity
  • Days 1-7: Azacitidine 75 mg/m 2 IV/SC once daily beginning on cycle 1 day 1
  • Continue until disease progression or unacceptable toxicity

Venetoclax plus decitabine (28-day cycle) [35]

  • Day 1: Venetoclax 100 mg PO once
  • Day 2: Venetoclax 200 mg PO once
  • Day 3: Venetoclax 300 mg PO once
  • Day 4 and beyond: Venetoclax 400 mg PO once daily
  • Days 1-5: Decitabine 20 mg/m 2 IV once daily beginning on cycle 1 day 1
  • Continue until disease progression or unacceptable toxicity

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!